NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Thursday reported a lack of $36.3 million in its third quarter.
The Newton, Massachusetts-based firm stated it had a lack of 45 cents per share.
The outcomes surpassed Wall Avenue expectations. The typical estimate of six analysts surveyed by Zacks Funding Analysis was for a lack of 56 cents per share.
The pharmaceutical firm posted income of $36.1 million within the interval, additionally beating Avenue forecasts. Six analysts surveyed by Zacks anticipated $34.8 million.
Karyopharm Therapeutics expects full-year income within the vary of $155 million to $165 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) utilizing information from Zacks Funding Analysis. Entry a Zacks stock report on KPTI at https://www.zacks.com/ap/KPTI